MHRA approves Seagen’s oral HER2 drug Tukysa

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission. 

Merck & Co signs multi-billion cancer drug development deal ...

Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics.

Seattle Genetics snags early approval for advanced breast ca...

The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain.

FDA sets August action date for Seattle’s oral HER2 drug tuc...

Seattle Genetics says data backs Padcev combo for first-line...

FDA backs Astellas/Seattle Genetics bladder cancer drug

The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead